Terasaki Institute for Biomedical Innovation and HTL Biotechnology Announce Memorandum of Understanding for Research in Translational Biomaterials
News provided by
Share this article
Share this article
LOS ANGELES, May 7, 2021 /PRNewswire/ The Terasaki Institute for Biomedical Innovation (TIBI), a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program. This program focuses on biomaterials for translational projects; it would combine TIBI s microneedle and bioprinting technologies with HTL s expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.